Sage Therapeutics Inc

-1.70 (-2.00%)
4:01:38 PM EDT: $83.24 -0.10 (-0.12%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)4.86B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.94 Million
Adjusted EPS-$2.11
See more estimates
10-Day MA$82.54
50-Day MA$84.68
200-Day MA$62.24
See more pivots

SAGE Therapeutics, Inc. Stock, NASDAQ:SAGE

215 1st Street, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.299.8380
Number of Employees: 675


SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.